Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07548840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Final enrollment: 34 participants (planned 30)
    • Interventions: TS-172 20~60 mg/day (Drug) to TS-172 20~60 mg/day (Drug)
    • Site details revised
    • Eligibility criteria shortened, about 5 words
  2. Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2026 to May 8, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on hemodialysis
Trial Details
NCT Number NCT07548840
Lead Sponsor Taisho Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Hyperphosphatemia Patients on Hemodialysis
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov